accurate information.

ICH Guidelines: ICH E6 and E3 provide guidance relevant to clinical trial labels and product information as part of Good Clinical Practice (GCP) and Clinical Study Reports (CSRs).

The aforementioned regulations make it necessary for companies to provide comprehensive product information, including but not limited to indications, dosage recommendations, and safety information, all in compliance with the governing legal framework.

Documentation

Effective documentation is vital to ensuring compliance and successful regulatory submissions. The following documentation points are essential:

• Product Information Leaflets (PILs): Must contain all legally required information presented in an accessible manner for patients.
• Summaries of Product Characteristics (SmPC): A critical document required by the MHRA that provides healthcare professionals with key information about the product.
• Labelling Artwork: Essential to store and review all artwork including changes made to ensure compliance with the latest regulations.

Labelling Review Process

The labelling review process should involve several critical stages:

1. Initial Draft Review: Engage RA, Quality Assurance (QA), and Clinical teams to draft the labelling.
2. Interdisciplinary Review: Involve Clinical, Pharmacovigilance, and Commercial teams to ensure all aspects are covered.
3. Regulatory Submission: Submit SmPC and PIL to the MHRA for approval.
4. Post-approval Changes: Monitor for necessary changes in labelling due to regulatory updates or new safety data.

Review/Approval Flow

The review and approval flow for labelling can be summarized in the following steps:

• Submission of Documents: Companies submit the SmPC, PIL, and mock-ups of the labelling artworks to the MHRA.
• MHRA Review: The MHRA assesses compliance with relevant regulations and may request additional information or clarification.
• Feedback Loop: The company should expect queries or requests for modification from the MHRA, providing timely and precise responses.
• Approval Issued: Once satisfied, the MHRA will issue a product licence or marketing authorisation allowing products to be marketed in the UK.

Common Deficiencies

During the labelling review process, the MHRA frequently identifies typical deficiencies that regulatory teams must be wary of:

• Inaccurate Product Information: Errors in indications, contraindications, or side effects can lead to significant delays or rejections.
• Missing Regulatory Information: Sometimes, mandatory information required by the MHRA may be omitted entirely.
• Non-compliance with Typeface or Size Regulations: The MHRA has specific requirements regarding font size and types; ignoring these can result in non-compliance.
• Poor Document Tracking: Inadequate oversight of document revisions and changes can complicate approval and impact product launch timelines.

Pharmacovigilance Considerations

Pharmacovigilance (PV) plays an integral part in ensuring that the labelling remains accurate post-approval. Companies must implement a system that captures adverse events and feeds this data back into the labelling process.

Pharmacovigilance Reporting Responsibilities

Regulatory teams must ensure compliance with the following pharmacovigilance responsibilities:

• Reporting: Prompt reporting of adverse drug reactions (ADRs) to the MHRA is critical to maintaining patient safety.
• Labelling Updates: Any new safety information must be incorporated into the labelling without delay.
• Continuous Risk Assessment: Ongoing assessment of the benefits and risks associated with the product.

Data Bridging Justification

When there is a need to update or change the labelling based on new data, companies must justify why existing data suffices instead of generating new evidence. Decision points to consider include:

• Whether existing studies provide sufficient evidence to support safety or efficacy claims.
• If real-world data can be leveraged as bridging data, reducing the need for new clinical studies.

Strategizing Labelling Compliance in International Markets

Governance over labelling ownership in global organizations requires careful strategizing to ensure compliance across different jurisdictions. The strategy should involve:

• Regional Adaptations: Consider variations in labelling needs across regions, including potential differences between US FDA and EU EMA requirements.
• Centralised vs Local Approvals: Determining whether regions can harmonize labelling through a central system or require localized approaches based on specific MHRA expectations.
• Collaborative Decision-Making: Engage Cross-Functional Teams (CFTs) in decision-making processes to ensure that all perspectives are considered.

Conclusion

Effective governance over UK labelling ownership within global organizations demands a robust understanding of the legal and regulatory landscape. Regulatory Affairs professionals must remain vigilant in their adherence to MHRA guidelines while collaborating with various departments to ensure the accuracy and safety of product information. By strategizing documentation, harnessing pharmacovigilance practices, and anticipating common deficiencies, organizations can facilitate compliant and effective product labelling in the UK market post-Brexit.

For further information and official guidance, refer to the MHRA’s Labelling Requirements and relevant ICH guidelines for a holistic understanding of the regulatory framework.